(Q38122396)

29 August 2017

title

GLP-1 receptor agonists: effects on cardiovascular risk reduction (English)

1 reference

29 August 2017

1 reference

Daniel Lorber

1

1 reference

29 August 2017

publication date

1 August 2013

1 reference

Cardiovascular Therapeutics

29 August 2017

published in

1 reference

29 August 2017

volume

31

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

238-249

1 reference

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Unraveling the science of incretin biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exenatide versus glibenclamide in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exenatide improves hypertension in a rat model of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Obesity and disease management: effects of weight loss on comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Behavioral aspects of weight loss in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12000

21 January 2018

Identifiers

DOI

10.1111/1755-5922.12000

1 reference

29 August 2017

1 reference